Niimura T, et al. Characterization of immune checkpoint inhibitor-induced myasthenia gravis using the US Food and Drug Administration Adverse Event Reporting System. J Clin Pharmacol. 2023;63:473–9.

Article  CAS  PubMed  Google Scholar 

•• Wang C, et al. Clinical characteristics, treatment, and outcome of nivolumab-induced myasthenia gravis. Invest New Drugs. 2023;41:333–9. This study collected case reports, reviews, case series and clinical studies for nivolumab-induced myasthenia gravis and summarized the clinical features and treatment.

Article  CAS  PubMed  Google Scholar 

•• Safa H, et al. Immune checkpoint inhibitor-related myasthenia gravis: single-center experience and systematic review of the literature. J ImmunoTherapy Cancer. 2019;7:319. This study compared between single-center patients and previously reported case series about the clinical demographics, management and outcome of ICI-induced MG.

Article  Google Scholar 

• Zhao S, et al. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis. Clin Exp Immunol. 2023;211:85–92. The Chinese databases described the diagnosis and management of pembrolizumab-induced myasthenia gravis.

Article  PubMed  Google Scholar 

Huang YT, et al. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol. 2020;11:634.

Article  PubMed  PubMed Central  Google Scholar 

Masi G, et al. Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis. Ann Clin Transl Neurol. 2023;10:825–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128–36. This study firstly reported the clinical characteristic of ICI-induced myasthenia gravis, collecting previously reported case series.

Article  CAS  PubMed  Google Scholar 

Weaver JMJ, et al. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: a case series. Support Care Cancer. 2023;31:518.

Article  PubMed  Google Scholar 

Zadeh S, et al. Novel uses of complement inhibitors in myasthenia gravis: two case reports. Muscle Nerve. 2024;69:368–72.

Article  PubMed  Google Scholar 

Kosick T, et al. A case of pembrolizumab-induced myasthenia gravis. Cureus. 2023;15:e45455.

PubMed  PubMed Central  Google Scholar 

Gao W, et al. Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis. J Immunother Cancer. 2022;10:e005970.

Article  PubMed  PubMed Central  Google Scholar 

Deharo F, et al. Immune checkpoint inhibitor-induced myositis/myocarditis with myasthenia gravis-like misleading presentation: a case series in intensive care unit. J Clin Med. 2022;11:5611.

Article  PubMed  PubMed Central  Google Scholar 

Oshima Y, Fujii S, Horiuchi K. Pembrolizumab-induced myasthenia gravis relapse after immunosuppressive therapy. Intern Med. 2022;61:3281–5.

Article  PubMed  PubMed Central  Google Scholar 

Verma N, et al. Rituximab for immune checkpoint inhibitor myasthenia gravis. Cureus. 2021;13:e16337.

PubMed  PubMed Central  Google Scholar 

Liamg S, et al. Immune myocarditis overlapping with myasthenia gravis due to anti-PD-1 treatment for a chordoma patient: a case report and literature review. Front Immunol. 2021;12:682262.

Article  Google Scholar 

Heleno C, et al. Myasthenia gravis as an immune-mediated side effect of checkpoint inhibitors. Cureus. 2021;13:e16316.

PubMed  PubMed Central  Google Scholar 

Lie DN, et al. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome. Am J Emerg Med. 2021;46:51–5.

Article  Google Scholar 

Nakanishi S, et al. A case report of nivolumab-induced myasthenia gravis and myositis in a metastatic renal cell carcinoma patient. Uro Case Rep. 2020;29:101105.

Google Scholar 

Narayanaswami P, et al. International Consensus Guidance for management of myasthenia gravis: 2020 update. Neurology. 2020;96:114–22.

Article  PubMed  Google Scholar 

• Longinow J, et al. Immune checkpoint inhibitor-induced myocarditis, myasthenia gravis, and myositis: a single-center case series. Cancer Med. 2023;12:2281–9. This study describes the clinical feature of small sample size with overlapping syndrome of ICI-induced myocarditis, myasthenia gravis and myositis, and reports the mortality and possible predictor of overlap syndrome.

Article  CAS  PubMed  Google Scholar 

Phua CS, et al. Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer. BMJ Neurol Open. 2020;2:e000028.

Article  PubMed  PubMed Central  Google Scholar 

Ünlütürk Z, et al. Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor. J Neuro Rural Pract. 2023;14:143–4.

Article  Google Scholar 

Yin B, et al. Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: a case report and review of the literature. Front Med. 2022;9:950801.

Article  Google Scholar 

• Pathak R, et al. Immune checkpoint inhibitor-induced myocarditis with myositis/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021;26:1052–61. This study focus on the management and outcome of ICI-induced overlap syndrome by analyzing previously reported case series and clinical study.

Article  PubMed  PubMed Central  Google Scholar 

Gao W, et al. Rechallenge of immune checkpoint inhibitors in case with adverse events including myasthenia gravis. J ImmuoTherapy Cancer. 2022;10:e005970.

Article  Google Scholar 

Suarez-Almazor ME, et al. The Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Support Care Cancer. 2020;28:6159–73.

Article  PubMed  Google Scholar 

Narayanaswami P, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96:114–22.

Article  PubMed  PubMed Central  Google Scholar 

Tahir N, et al. Nivolumab, a double-edged Sword: a case report of nivolumab-induced myasthenia gravis. J Med Cases. 2021;12:424–8.

Article  PubMed  PubMed Central  Google Scholar 

Shimozaki K, et al. Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data. Future Oncol. 2021;17:2593–603.

Article  CAS  PubMed  Google Scholar